GlassScriptPhysician profile
Ronald G Beasley
NPI 1790186625
$4,320.29
in general payments reported to CMS, 2019-2025
34 companies · $421 in 2025
The $421 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,640 · 2022: $1,041 · 2023: $547 · 2024: $672 · 2025: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,529 · Education: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,528.78 |
| Education | $110.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $758.36 | 2021-2025 | Mounjaro, Jardiance |
| Novo Nordisk INC | $430.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $328.18 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $293.39 | 2021-2025 | |
| Amgen INC. | $271.07 | 2021-2025 | Otezla, Repatha, Otezla |
| Astellas Pharma US INC | $230.68 | 2021-2023 | |
| Corcept Therapeutics | $226.29 | 2021-2023 | Korlym |
| Takeda Pharmaceuticals U.S.A., INC. | $219.10 | 2021-2022 | |
| Glaxosmithkline, LLC. | $196.97 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $150.19 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbott Laboratories | $130.82 | 2021-2024 | Freestyle Libre 3 |
| Avanir Pharmaceuticals, INC. | $124.02 | 2021 | |
| Amarin Pharma, INC. | $102.48 | 2021-2023 | |
| Lundbeck LLC | $83.61 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $75.99 | 2023-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $72.29 | 2022-2023 | |
| Esperion Therapeutics, INC. | $68.48 | 2021 | |
| Pfizer INC. | $60.59 | 2022-2024 | |
| Horizon Therapeutics Plc | $53.29 | 2021-2022 | |
| Exact Sciences Corporation | $50.53 | 2024-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $48.74 | 2024 | |
| Currax Pharmaceuticals LLC | $40.32 | 2023-2025 | Nexletol, Contrave |
| Atland Pharmaceuticals, LLC | $39.65 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Sumitomo Pharma America, INC. | $34.86 | 2024-2025 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $30.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $28.81 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.20 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.92 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $25.54 | 2021 | |
| Xeris Pharmaceuticals, INC. | $22.50 | 2023 | Recorlev |
| Clarus Therapeutics INC. | $20.92 | 2021 | |
| Surmodics, INC. | $17.83 | 2025 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Pounce Thrombectomy System |
| Antares Pharma, INC. | $17.13 | 2022 | |
| Acerus Pharmaceuticals Corporation | $12.55 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.